Jounce Therapeutics Inc. (NASDAQ:JNCE) price closed higher on Tuesday, September 14, jumping 11.90% above its previous close.
A look at the daily price movement shows that the last close reads $6.47, with intraday deals fluctuated between $7.06 and $7.44. The company’s 5Y monthly beta was ticking 1.11. Taking into account the 52-week price action we note that the stock hit a 52-week high of $14.84 and 52-week low of $5.03. The stock added 37.90% on its value in the past month.
Jounce Therapeutics Inc., which has a market valuation of $384.95 million, is expected to release its quarterly earnings report Nov 04, 2021 – Nov 08, 2021. Analysts tracking JNCE have forecast the quarterly EPS to shrink by -0.44 per share this quarter, while the same analysts predict the annual EPS to hit -$1.39 for the year 2021 and up to -$2 for 2022. In this case, analysts estimate an annual EPS growth of -12.10% for the year and -43.90% for the next year.
Staying with the analyst view, there is a consensus estimate of $46.15 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -26.00% below that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give JNCE a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 8 analysts have assigned JNCE a recommendation rating as follows: 2 rate it as a Hold; 3 advise Buy while 2 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Jounce Therapeutics Inc. (JNCE) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that JNCE’s price is at present 19.16% off the SMA20 and 25.79% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 71.65, with weekly volatility standing at 4.94%. The indicator jumps to 5.56% when calculated based on the past 30 days. Jounce Therapeutics Inc. (NASDAQ:JNCE)’s beta value is holding at 1.10, while the average true range (ATR) indicator is currently reading 0.35. Considering analysts have assigned the stock a price target range of $10.00-$17.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $14.50. Based on this estimate, we see that current price is roughly -38.12% off the estimated low and -134.81% off the forecast high. Investors will no doubt be excited to see the share price fall to $15.00, which is the median consensus price, and at that level JNCE would be -107.18% from current price.
Turning out attention to how the Jounce Therapeutics Inc. stock has performed in comparison to its peers in the industry, here’s what we find: JNCE’s stock is 11.90% on the day and -18.19% in the past 12 months, while Molecular Templates Inc. (MTEM) traded -4.46% in the last session and was positioned -56.96% down on its price 12 months ago. Elsewhere in the market, the S&P 500 Index has stumbled -0.57% in last trading session, with the Dow Jones Industrial also saw a negative session on the day with -0.84%.
An analysis of the Jounce Therapeutics Inc. (NASDAQ:JNCE) stock in terms of its daily trading volume indicates that the 3-month average is 477.50K.
Current records show that the company has 51.21M in outstanding shares. The insiders’ percentage holdings are 0.30% of outstanding shares while the percentage share held by institutions stands at 71.00%. But the 3.43% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.